ArticlePloS one2025
A computational study exploring echinoderm-derived compounds for inhibition of aminoglycoside acetyltransferases.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A liquid handling platform for standardized quantification of cell-free enzymatic activity encoded by antimicrobial resistance genes.Synthetic biology (Oxford, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aminoglycoside acetyltransferases (AACs) catalyze the acetylation of aminoglycoside antibiotics, playing a major role in bacterial resistance and posing a serious threat to global healthcare. Despite growing interest in natural products, echinoderm-derived metabolites remain largely unexplored as AAC inhibitors. This study presents a comprehensive in-silico investigation into the potential of these marine compounds to inhibit four key AAC enzymes: Aminoglycoside 2'-N-acetyltransferase, AAC(3)-Ib, AAC(6')-Im, and AAC(3)-Iva. A virtual screening of 1600 echinoderm metabolites was performed using molecular docking, ADMET profiling, and 100 ns molecular dynamics simulations. The top 10 compounds against each enzyme were shortlisted based on binding affinity, with CMNPD15515, CMNPD17440, CMNPD3088, and CMNPD29853 showing the most stable interactions and highest binding energies. These compounds consistently outperformed native aminoglycoside ligands in docking scores and MMGBSA binding free energy calculations, suggesting stronger inhibitory potential. While a few top hits exhibited violations of Lipinski's Rule of Five particularly in molecular weight their strong target engagement and stable dynamic profiles support their candidacy as lead molecules. This work underscores the evolutionary and structural uniqueness of echinoderm metabolites as a promising reservoir for antibiotic adjuvants. It also establishes a computational framework for prioritizing marine natural products against antibiotic resistance targets. Although experimental validation remains essential, this study provides compelling early evidence to guide future in vitro and in vivo research toward the development of novel AAC inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.